OR WAIT null SECS
Nonacus has revealed the launch of its new capture kit, ExomeCG, which has been designed to simplify molecular and cytogenomics data generation and interpretation.
Nonacus, a UK-based precision medicine company, has revealed in an Oct 16, 2019 press release the launch of its new capture kit, ExomeCG, which has been designed to simplify molecular and cytogenomics data generation and interpretation.
The clinically enhanced genome capture kit has been co-developed with Congenica, which is a digital health technology company that specializes in software solutions for the accelerated interpretation of complex genomic data. As ExomeCG is a clinically validated test, it is possible to use it in place of chromosomal microarray and multiplex ligation-dependent probe amplification (MLPA) front line tests, ultimately reducing costs and shortening timescales.
“The launch of ExomeCG enables us to deliver a comprehensive clinical bioinformatics service to our customers and advance clinical cytogenomics by providing a robust, cost effective, and user-friendly laboratory and analysis workflow,” said Chris Sale, chief executive officer of Nonacus, in the press release. “The current cytogenomics paradigm typically requires a multi-test strategy whereby chromosomal microarrays are first run achieving a modest 15% diagnostic yield. Subsequently, exome sequencing is undertaken in order to raise the diagnostic yield to around 40%. ExomeCG now offers a validated single test solution, enabling customers to obtain the highest diagnostic yield while removing additional workflows and the associated time and costs.”